Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Instil Bio, Inc.NASDAQ: TIL

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities rises 150.8% from a year ago

Other current liabilities stood at $2.25M at the end of Q1 FY2026, up 150.8% from a year earlier and down 10.5% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.

Context

  • Other current liabilities amounted to 1.1% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +150.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.25M-10.5% QoQ
Last fiscal yearDec 2025
$2.52M+21.4% YoY
Year agoMar 2025
$898K+150.8% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+150.8%——
1 year+21.4%——
3-year CAGR-15.9%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
2.52M USD
Year-over-year change
+21.4%
4-year CAGR
-34.5%

Other Current Liabilities vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +150.8% is the highest of 7, against a peer median of -4.9%.
  • Other current liabilities amounts to 1.1% of total assets for TIL, versus a peer median of 1.1%.
TIL Competitors
Other Current Liabilities for TIL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$18.82M USD—+243.1%7.4%
MGNXMacroGenics, Inc.Mar 2026$18.45M USD—-8.5%8.5%
IFRXInflaRx N.V.Mar 2026€10.13M EUR+36.3%—20.7%
PLRXPliant Therapeutics, Inc.Mar 2026$2.29M USD-57.4%+4.8%1.1%
TILInstil Bio, Inc.Mar 2026$2.25M USD+150.8%-15.9%1.1%
STTKShattuck Labs, Inc.Mar 2026$1.09M USD-44.2%-19.9%1.1%
WHWKWhitehawk Therapeutics IncMar 2026$778K USD+48.5%+26.2%0.6%
SRZNSurrozen, Inc.Mar 2026$340K USD+34.4%-20.8%0.3%
ONCYOncolytics Biotech Inc.Mar 2026CA$0 CAD-100.0%+246.9%0.0%
Peer median (excluding TIL) —-4.9%+4.8%1.1%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.59M43.72M9.2M8.81M6.64M
Short-term Investments416.51M217.2M141.16M104.51M69.49M
Net Receivables0000848K
Inventory00000
Other Current Assets08.46M1.5M1.83M112.41M
Total Current Assets464.02M269.38M160.76M124.47M191.43M
Property, Plant & Equipment (Net)122M209.34M141.07M130.34M364K
Goodwill5.72M0000
Intangible Assets10.1M0000
Long-term Investments0023.16M00
Tax Assets00000
Other Non-current Assets8.14M3.41M639K8.76M11.73M
Total Non-current Assets145.96M212.75M164.87M139.1M12.09M
Total Assets609.98M482.13M325.63M263.57M203.52M
Account Payables5.57M2.36M1.21M659K779K
Short-term Debt00000
Tax Payables524K0000
Deferred Revenue00000
Other Current Liabilities13.66M4.23M1.22M2.07M2.52M
Total Current Liabilities41.36M32.79M10.56M7.9M4.84M
Long-term Debt072.35M81.43M84.19M84.81M
Deferred Tax Liabilities2.43M0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities11M8.21M4.94M1.03M8K
Total Non-current Liabilities13.43M85.74M89.24M86.24M84.81M
Total Liabilities54.78M118.52M99.8M94.13M89.66M
Common Stock00000
Retained Earnings(201.72M)(424.89M)(580.98M)(655.12M)(726.49M)
Accumulated OCI(87K)(493K)(348K)(228K)(583K)
Other Stockholders Equity000(0)0
Minority Interest00000
Total Equity555.2M363.61M225.83M169.44M113.87M
Total Debt079.9M86.05M86.89M85.18M
Net Debt(37.59M)36.19M76.86M78.08M78.54M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.